Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation.
Ferris RL, Lenz HJ, Trotta AM, García-Foncillas J, Schulten J, Audhuy F, Merlano M, Milano G. Ferris RL, et al. Among authors: trotta am. Cancer Treat Rev. 2018 Feb;63:48-60. doi: 10.1016/j.ctrv.2017.11.008. Epub 2017 Dec 2. Cancer Treat Rev. 2018. PMID: 29223828 Free PMC article. Review.
Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy.
Trotta AM, Ottaiano A, Romano C, Nasti G, Nappi A, De Divitiis C, Napolitano M, Zanotta S, Casaretti R, D'Alterio C, Avallone A, Califano D, Iaffaioli RV, Scala S. Trotta AM, et al. Cancer Immunol Res. 2016 Apr;4(4):366-74. doi: 10.1158/2326-6066.CIR-15-0184. Epub 2016 Jan 27. Cancer Immunol Res. 2016. PMID: 26817995
Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F, Di Gennaro E, Ionna F, Longo F, Aversa C, Pavone E, Maglione MG, Di Marzo M, Muto P, Cavalcanti E, Petrillo A, Sandomenico F, Maiolino P, D'Aniello R, Botti G, De Cecio R, Losito NS, Scala S, Trotta A, Zotti AI, Bruzzese F, Daponte A, Calogero E, Montano M, Pontone M, De Feo G, Perri F, Budillon A. Caponigro F, et al. BMC Cancer. 2016 Nov 25;16(1):918. doi: 10.1186/s12885-016-2957-y. BMC Cancer. 2016. PMID: 27884140 Free PMC article. Clinical Trial.
Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol.
Ottaiano A, Scala S, Normanno N, Napolitano M, Capozzi M, Rachiglio AM, Roma C, Trotta AM, D'Alterio C, Portella L, Romano C, Cassata A, Casaretti R, Silvestro L, Nappi A, Tafuto S, Avallone A, De Stefano A, Tamburini M, Picone C, Petrillo A, Izzo F, Palaia R, Albino V, Amore A, Belli A, Pace U, Di Marzo M, Chiodini P, Botti G, De Feo G, Delrio P, Nasti G. Ottaiano A, et al. Among authors: trotta am. BMC Cancer. 2019 Sep 9;19(1):899. doi: 10.1186/s12885-019-6109-z. BMC Cancer. 2019. PMID: 31500586 Free PMC article.
In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies.
Ieranò C, Righelli D, D'Alterio C, Napolitano M, Portella L, Rea G, Auletta F, Santagata S, Trotta AM, Guardascione G, Liotti F, Prevete N, Maiolino P, Luciano A, Barbieri A, Di Mauro A, Roma C, Esposito Abate R, Tatangelo F, Pacelli R, Normanno N, Melillo RM, Scala S. Ieranò C, et al. Among authors: trotta am. J Immunother Cancer. 2022 Mar;10(3):e004032. doi: 10.1136/jitc-2021-004032. J Immunother Cancer. 2022. PMID: 35246475 Free PMC article.
Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients.
Napolitano M, D'Alterio C, Cardone E, Trotta AM, Pecori B, Rega D, Pace U, Scala D, Scognamiglio G, Tatangelo F, Cacciapuoti C, Pacelli R, Delrio P, Scala S. Napolitano M, et al. Among authors: trotta am. Oncotarget. 2015 Apr 10;6(10):8261-70. doi: 10.18632/oncotarget.3014. Oncotarget. 2015. PMID: 25823653 Free PMC article.
Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients.
Santagata S, Rea G, Bello AM, Capiluongo A, Napolitano M, Desicato S, Fragale A, D'Alterio C, Trotta AM, Ieranò C, Portella L, Persico F, Di Napoli M, Di Maro S, Feroce F, Azzaro R, Gabriele L, Longo N, Pignata S, Perdonà S, Scala S. Santagata S, et al. Among authors: trotta am. Br J Cancer. 2024 May 4. doi: 10.1038/s41416-024-02702-x. Online ahead of print. Br J Cancer. 2024. PMID: 38704478
32 results